A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · DOUBLE
- Evidence population
- Human clinical study registration
- Participants
- 311
- Population
- ALL · 50 Years
- Duration
- 2025-02-28 to 2030-11-23
- Intervention
- Ixo-vec; Aflibercept
- Comparator
- Aflibercept
- Outcomes measured
- Mean change from Baseline in Best-Corrected Visual Acuity (BCVA) based on an average at Weeks 52 and 56 — Baseline, Wee…; Mean number of aflibercept IVT injections received — Week 4 through Week 56; Percentage of participants with worsened BCVA from Baseline through Week 56 and Week 104 — Baseline through Week 56 and…; Percentage of participants with improved BCVA from Baseline through Week 56 and Week 104 — Baseline through Week 56 and…; Mean change from Baseline in BCVA through Week 104 — Baseline through Week 104; Mean change from Week 1 in BCVA based on an average at Weeks 52 and 56 and at Week 104 — Week 1 to Week 56 and Week 104; Percentage of participants with BCVA of 73 letters or more from Week 4 through Week 56 and Week 104 — Week 4 through We…; Mean change in Central Subfield Thickness (CST) from Baseline to Week 56 and Week 104 — Baseline to Week 56 and Week 104; Percentage of participants with CST ≤ 300 μm at Week 56 and Week 104 — Week 56 and Week 104; Mean number of CST fluctuations > 50 μm from Week 1 through Week 56 and Week 104 — Week 1 through Week 56 and Week 104; Percentage of participants with CST fluctuations > 50 μm from Week 1 through Week 56 and Week 104 — Week 1 through Week…; Mean number of aflibercept IVT injections received from Week 4 through Week 104 — Week 4 through Week 104; Percent reduction in mean rate of annualized anti-Vascular Endothelial Growth Factor (VEGF) injections after 56 weeks a…; Percentage of participants who were aflibercept injection-free — Week 4 through Week 56 and through Week 104; Percentage of participants who received 0 or 1 aflibercept injection — Week 4 through Week 56 and through Week 104; Percentage of participants who receive 0, 1, or 2 aflibercept injections from Week 4 through Week 56 and through Week 1…; Mean change in area of Choroidal Neovascularization (CNV) lesion from Baseline through Week 104 — Baseline through Week…; Mean change in macular volume from Baseline through Week 104 — Baseline through Week 104; Percentage of participants without Intraretinal Fluid (IRF) through Week 104 — Through Week 104; Percentage of participants without Subretinal Fluid (SRF) through Week 104 — Through Week 104
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.